Inventor Dr. Mehmet Ali SÖYLEMEZ discovered first time, the utility of the biomarker PROCALCITONIN in DIABETES MELLITUS and DIABETIC FOOT SYNDROME. More than 50 peer reviewed* publications have followed, substantiating PROCALCITONIN as one of the most promising biomarker tools for DIABETES MELLITUS and DIABETIC FOOT SYNDROME of healthcare.
The method is useful for performing in vitro diagnosis of pancreatic diabetes mellitus and/or pancreatic diabetes mellitus complications chosen from diabetic microangiopathy, retinopathy, nephropathy, neuropathy, retinopathy, macroangiopathy and diabetic foot syndrome and/or risk stratification of pancreatic diabetes mellitus, for assessing degree of severity and for assessing the course of pancreatic diabetes mellitus,
preferably type II diabetes mellitus, and its sequelae and concomitant illnesses, preferably endothelial dysfunction, hyperlipoproteinemia, hypertensive dysregulation of the cardiovascular system, diabetic microangiopathy, retinopathy, nephropathy, renal insufficiency, neuropathy, macroangiopathy, diabetic foot syndrome and cardiovascular complications (all claimed).